Comparing two treatments for HER2-positive breast cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have HER2-positive breast cancer that has spread or cannot be surgically removed.
- You must have already been treated with trastuzumab and a type of chemotherapy called taxane.
- Your cancer must have at least one measurable tumor as seen on scans.
- You must be well enough to perform daily activities (ECOG score of 0 or 1).
- You must not have received any other anti-HER2 antibody drug conjugate therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.